Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
7 hedge funds and large institutions have $3.8K invested in Viracta Therapeutics, Inc. Common Stock in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 26 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
78% less funds holding
Funds holding: 32 → 7 (-25)
96% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 26
99% less capital invested
Capital invested by funds: $583K → $3.8K (-$579K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$13.4K |
| 2 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$757 |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$68 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$262K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$46.6K |
| 3 |
ACM
Aisling Capital Management
New York
|
-$46.2K |
| 4 |
Renaissance Technologies
New York
|
-$46.1K |
| 5 |
BlackRock
New York
|
-$37.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OC
26
Oarsman Capital
Milwaukee,
Wisconsin
| – | -$161 | -1,000 | Closed |
|
27
JP Morgan Chase
New York
| – | -$116 | -721 | Closed |
|
|
ITIM
28
Indiana Trust & Investment Management
Mishawaka,
Indiana
| – | -$32 | -200 | Closed |
|
|
SS
29
SBI Securities
Tokyo,
Japan
| – | -$29 | -180 | Closed |
|
30
Wells Fargo
San Francisco,
California
| – | -$28 | -171 | Closed |
|
|
AA
31
Addison Advisors
Middlebury,
Vermont
| – | -$1 | -4 | Closed |
|
|
32
Simplex Trading
Chicago,
Illinois
| – | +$68 | +400 | New |
|
VIRX Hedge Fund Activity: Q1 2025 in Review
7 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q1 2025, worth a combined $3.8K — down 99% from $583K a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of VIRX and 1 opened new positions — a net loss of 25 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was XTX Topco, adding an estimated $13.4K. The largest seller was Citadel Advisors, exiting entirely with an estimated $262K sold.
- 7 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q1 2025, down from 32 in Q4 2024.
- Funds reported $3.8K of Viracta Therapeutics, Inc. Common Stock stock for Q1 2025, down 99% quarter-over-quarter.
- 1 fund opened new Viracta Therapeutics, Inc. Common Stock positions in Q1 2025 and 26 closed out, a net change of -25 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q1 2025 was XTX Topco, an estimated $13.4K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q1 2025 was Citadel Advisors, an estimated $262K sold.
Based on aggregated 13F filings for Q1 2025.